May 15, 2019 / 12:00PM GMT
Operator
Good morning, and welcome to ImmunoGen Regulatory Update Call. Today's conference is being recorded.
At this time, I'd like to turn the conference over to Sarah Kiely, Head of Investor Relations. Please go ahead.
Sarah Cue Kiely - ImmunoGen, Inc. - IR & Corporate Communications Officer
Thank you. Earlier today, we issued a press release following a recent meeting with FDA to discuss the results of the Phase III FORWARD I trial and a registration pathway for mirvetuximab monotherapy. This press release and recording of the call can be found under the Investors & Media section of our website at immunogen.com.
On the call today are Mark Enyedy, our President and CEO; and Anna Berkenblit, our Chief Medical Officer. During the discussion, we will use forward-looking statements, and our actual results may differ materially from such statements. Descriptions of the risks and uncertainties associated with an investment in ImmunoGen are included in our SEC filings.
I'll now turn the call over to Mark.
Mark J. Enyedy
ImmunoGen Inc to Discuss Recent Regulatory Meeting with FDA Conference Call Transcript
May 15, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers